Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its anti-obesity treatments.
The company, which recently changed its CEO and announced it will lay off 9,000 employees, set an extraordinary shareholders meeting for November 14 following a disagreement between the board and majority shareholder over its future governance.
